FILSPARI Expansion And Aging Trends Will Advance Precision Therapies
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 14 Analysts
Published
22 Aug 25
Updated
22 Aug 25
AnalystHighTarget's Fair Value
US$47.00
61.9% undervalued intrinsic discount22 Aug
US$17.92
1Y
99.6%7D
-4.8%